LAIPLALAIPLA
LAIPLALAIPLA
  • About
    • About LAIPLA
    • Ambassador Outreach Program
    • Board of Directors
    • Committees
    • Administration
    • Member Firms and Companies
    • Past Presidents
    • Recent Past Presidents
    • Public Service Award
    • Diversity Fellowship
    • Bylaws
  • Events
  • Membership
  • Sponsorship
  • Contact
  • About
    • About LAIPLA
    • Ambassador Outreach Program
    • Board of Directors
    • Committees
    • Administration
    • Member Firms and Companies
    • Past Presidents
    • Recent Past Presidents
    • Public Service Award
    • Diversity Fellowship
    • Bylaws
  • Events
  • Membership
  • Sponsorship
  • Contact

UK High Court Invalidates Shionogi EPC Patent to HIV Drug “Tivicay”

November 25, 2016| in Wegner's Writings| by Hal Wegner

Today in Merck Sharp and Dohme Ltd. v. Shionogi & Co Ltd., [2016] EWHC 2989 (Pat)(High Court 2016)(Arnold, J.), the High Court invalidated Shionogi’s European Patent (UK) No. 1 422 218. This patent covers Shionogi’s anti-HIV drug “Tivicay”.

Noninfringement:  The Court thus reached a conclusion of no infringement as to the MSD drug “Isentress” on the basis of invalidity.

The opinion of the High Court is attached.

shionogipatentnov25

Regards
Hal

 

IP Blog Categories

  • Announcements
  • Events
  • LAIPLA News
  • The TTABlog
  • Uncategorized
  • Wegner's Top 10
  • Wegner's Writings

Archives

Previous

The Lee Patent Legacy — Addendum

Next

Rules Change Keyed to the Global Dossier Initiative (con’d): Machine Translations


Since 1934, LAIPLA has been educating and connecting members of the local intellectual property legal community

Pages

About 
Events
Membership
Sponsorship
Contact
Privacy Policy

Search
Contact

LAIPLA
1621 W 25th Street
Box 633
San Pedro, CA 90732
Phone: (323) 285-1654
Fax: ( 310) 878-0517
Email: office@laipla.net

© 2025 Los Angeles Intellectual Property Law Association. All Rights Reserved | Website design by Arclight Digital.